Sign in

Daniel Fuster

@danfuster.bsky.social
355 followers 463 following 13 posts

Nephrologist and physician-scientist at Inselspital Bern, Switzerland. Kidney stone and rare kidney disease enthusiast. Passion for climbing, skiing and mountaineering.

PostsRepliesMedia
Daniel Fuster @danfuster.bsky.social · 17/06/2025
Thank you Swiss National Science Foundation !! We just received 3.42 Mio CHF funding for our EMPASTONE trial. Looking forward to working with colleagues in Switzerland, Germany, France, Italy and the UK. clinicaltrials.gov/study/NCT066...
clinicaltrials.gov
ClinicalTrials.gov
260
Reposted by Daniel Fuster
markusathome @markusathome.bsky.social · 11/04/2025
Our new webinar in german language: SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz) WATCH NOW: youtu.be/i_YTcIQ4YQk?... @danfuster.bsky.social @gunnarheine.bsky.social @marcussaemann.bsky.social
youtu.be
SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz)
YouTube video by MARKUS at HOMe
074
Daniel Fuster @danfuster.bsky.social · 28/03/2025
Just out in Nature Communications…..a mystery solved. It’s all about lipids in the regulation of intracellular NHEs. Thank you David for this great collaboration. rdcu.be/efxE2
rdcu.be
PIP2-mediated oligomerization of the endosomal sodium/proton exchanger NHE9
Nature Communications - Na+ /H+ exchangers regulate intracellular pH, sodium levels, and cell volume. Cryo-EM structures reveal lipid coordination at the dimer interfaces of NhaA with cardiolipin...
131
Reposted by Daniel Fuster
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 19/03/2025
So @danfuster.bsky.social and colleagues seem to find HCTZ doesn’t work for anything! In a post hoc analysis of NOSTONE (where CT scans were done in all & repurposed for calculating bone density) HCTZ doesn’t increase it vs placebo journals.lww.com/cjasn/pages/... in @asnpublications.bsky.social
visual abstract of NOSTONE and bone density from Hector
165
Reposted by Daniel Fuster
markusathome @markusathome.bsky.social · 12/03/2025
Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney Stones: A Post Hoc Analysis of the NOSTONE Trial by Drs. Christe, @danfuster.bsky.social et al. journals.lww.com/cjasn/abstra... HCTZ up to 50 mg daily did not preserve BMD compared to placebo over 3 years!
031
Reposted by Daniel Fuster
Pedro H. Imenez Silva @imenezpedro.bsky.social · 04/03/2025
Happy to share that our research letter has been accepted in @ndt-era.bsky.social. Here we showed that impaired renal acid excretion is strongly associated with CaOx stone presence in the Swiss Kidney Stone Cohort: bit.ly/41rKodu. Many thanks to all co-authors in Switzerland for their support.
bit.ly
Acid excretion is impaired in calcium oxalate stone formers
Pedro H Imenez Silva, Nasser A Dhayat, Daniel G Fuster, Harald Seeger, Alexander Ritter, Thomas Ernandez, Florian Buchkremer, Beat Roth, Olivier Bonny, Isa
063
Daniel Fuster @danfuster.bsky.social · 10/03/2025
HCTZ not better than placebo for the prevention of BMD loss among individuals with calcium kidney stones journals.lww.com/cjasn/abstra...
journals.lww.com
Hydrochlorothiazide and Bone Mineral Density in Patients... : Clinical Journal of the American Society of Nephrology
three-year period. Methods: This post-hoc analysis was conducted on data from the NOSTONE trial, a multicenter, randomized, controlled study. A total of 416 adults with recurrent calcium stones par...
061
Daniel Fuster @danfuster.bsky.social · 02/01/2025
Excited to share the results of our SWEESTONE trial 🔥🔥🔥@NatureMedicine Wonderful collaboration with colleagues @unibern @inselgruppe and DCR Bern. www.nature.com/articles/s41... Empagliflozin substantially reduced urinary supersaturations in non-diabetic patients with kidney stones.
nature.com
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial - Nature Medicine
As part of the SWEETSTONE trial, the authors report the ability of the sodium-glucose cotransporter 2 inhibitor empagliflozin to reduce the likelihood of kidney stone formation in individuals without ...
1128
Daniel Fuster @danfuster.bsky.social · 14/12/2024
Chlorthalidone is not better than hydrochlorothiazide in kidney outcome prevention in a secondary analysis of the large DCP study. Very important results. jamanetwork.com/journals/jam...
jamanetwork.com
Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes
This secondary analysis of a randomized clinical trial examines whether chlorthalidone is superior to hydrochlorothiazide in preventing kidney outcomes in patients with hypertension.
140
Reposted by Daniel Fuster
Florian Buchkremer @swissnephro.bsky.social · 07/12/2024
… and you might even dream (or fool yourself?) about achieving lower sodium intake in your patients, but the most likely explanation for the negative result of #NOSTONE, is just that: Thiazides do not work very well in preventing recurrent kidney stones. 2/2
021
Reposted by Daniel Fuster
Florian Buchkremer @swissnephro.bsky.social · 07/12/2024
I’m biased (local PI, steering committee), but the quality of #NOSTONE far exceeds most (if not all) data that the critics base their many assumptions and beliefs on. You can speculate about the additional effects of citrate or a different type or dose of diuretic, … 1/2
121
Daniel Fuster @danfuster.bsky.social · 21/11/2024
Acidosis and CKD journals.lww.com/cjasn/citati... "Whether there will be a definitive, adequately powered trial of this inexpensive, fairly safe intervention in CKD is up to funding agencies to decide" Cardiology is doing large outcome trials with colchicine - why can we not do this with alkali ?
journals.lww.com
1102